FELIX BAKER
CIK 1087940 · last filed 2026-07-16
FELIX BAKER is a corporate insider who has filed 291 SEC Form 4 insider transactions across 31 companies since 2007. The most recent filing shows the insider sold $1.27B of CELC on Jul 16, 2026. Across all open-market trades the lifetime net is +$1.52B, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $2.66B across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.66B
Companies
31
Total Filings
291
Lifetime Open-Market Net
$1.52B
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CELC | 442,940 | $82.54 | $36.56M | -$1.27B | 1 | 2026-07-16 | |
| INCY | Director | 3,115,871 | $131.75 | $410.50M | -$15.68M | 30 | 2026-06-10 |
| KNSA | Director | 2,759,734 | $80.05 | $220.92M | $324.00M | 4 | 2026-06-02 |
| VTVT | Director | 12,368 | $31.23 | $386.2K | $0 | 2 | 2025-09-05 |
| MDGL | Director | 1,796,261 | $540.18 | $970.30M | $0 | 2 | 2025-06-24 |
| DBVT | Director | — | $13.61 | — | $0 | 1 | 2025-03-31 |
| ONC | Director | 730,643 | $329.96 | $241.08M | -$1.14B | 1 | 2025-02-28 |
| IGM Biosciences, Inc. (IGMS) Delisted | Director | 3,123,770 | $1.27 | $3.97M | $20.59M | 2 | 2024-03-14 |
| Neurogene Inc. (NLTX) Delisted | Director | 39,081 | $13.96 | $545.6K | $38.80M | 3 | 2023-10-10 |
| TRDA | 10%+ Owner | 360,122 | $5.84 | $2.10M | $2.77M | 2 | 2022-06-06 |
| KOD | Director | 14,393,675 | $39.94 | $574.88M | $436.10M | 5 | 2022-02-17 |
| Talis Biomedical Corp (TLIS) Delisted | Director | 470,212 | $2.84 | $1.34M | $1.31M | 1 | 2021-11-19 |
| Seagen Inc. (SGEN) Delisted | Director | 4,124,966 | $228.74 | $943.54M | $2.56B | 33 | 2021-05-18 |
| BeOne Medicines Ltd. (BGNE) Delisted | Director | 18,590 | $184.71 | $3.43M | -$160.29M | 1 | 2021-01-06 |
| PRLD | Director | 9,247,763 | $4.68 | $43.28M | $180.00M | 1 | 2020-09-30 |
| Atreca, Inc. (BCEL) Delisted | 10%+ Owner | — | $0.15 | — | $0 | 1 | 2020-07-20 |
| Neurogene Inc. (AQXP) Delisted | Director | 1,178,742 | — | — | $6.69M | 1 | 2019-08-08 |
| Aceragen, Inc. (IDRA) Delisted | Director | 5,249 | $7.22 | $37.9K | -$20.91M | 14 | 2019-04-03 |
| GENOMIC HEALTH INC (GHDX) Delisted | Director | 185,836 | — | — | -$232.16M | 49 | 2019-03-19 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | 10%+ Owner | 3,054,192 | $58.70 | $179.28M | $0 | 1 | 2016-04-01 |
| BCRX | 10%+ Owner | 2,145,586 | $9.74 | $20.91M | $7.12M | 7 | 2016-02-09 |
| SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Director | 50,111 | — | — | $270.67M | 14 | 2015-06-22 |
| ACAD | Director | 1,468,014 | $26.04 | $38.22M | $201.38M | 3 | 2013-06-11 |
| Ardea Biosciences, Inc./DE (RDEA) Delisted | Director | 116,454 | — | — | $93.93M | 18 | 2012-02-03 |
| VIROPHARMA INC (VPHM) Delisted | 10%+ Owner | 9,840,469 | — | — | $219.64M | 22 | 2011-12-16 |
| AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted | 10%+ Owner | 72,731 | — | — | -$7.68M | 5 | 2011-08-03 |
| RPRX | 10%+ Owner | 1,608,196 | $59.85 | $96.25M | $4.61M | 2 | 2010-06-02 |
| ALLOS THERAPEUTICS INC (ALTH) Delisted | 10%+ Owner | 83,205 | — | — | $14.68M | 15 | 2009-02-06 |
| NEUROGEN CORP (NRGN) Delisted | Director | 690,856 | — | — | $0 | 12 | 2008-11-13 |
| TAPESTRY PHARMACEUTICALS, INC (TPPH) Delisted | 10%+ Owner | 41,120 | — | — | -$173 | 1 | 2008-04-08 |
| Aceragen, Inc. (IDP) Delisted | 10%+ Owner | 502,680 | — | — | -$7.15M | 10 | 2007-12-07 |
Recent Filings
291 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-16 | CELC | Sell (S) | −12,400,000 | -$1.27B | EDGAR |
| 2026-06-10 | INCY | Grant (A) | +19,704 | $0 | EDGAR |
| 2026-06-02 | KNSA | Grant (A) | +72,936 | $0 | EDGAR |
| 2025-09-05 | VTVT | Grant (A) | +306,000 | $0 | EDGAR |
| 2025-06-24 | MDGL | Grant (A) | +17,160 | $0 | EDGAR |
| 2025-03-31 | DBVT | Grant (A) | — | $0 | EDGAR |
| 2025-02-28 | ONC | Sell (S) | −4,396,962 | -$1.14B | EDGAR |
| 2024-10-08 | KNSA | Grant (A) | +56,760 | $0 | EDGAR |
| 2024-06-27 | MDGL | Grant (A) | +17,136 | $0 | EDGAR |
| 2024-05-09 | INCY | Exer (M) | +180,000 | $8.82M | EDGAR |
Showing 1–10 of 291
Page 1 of 30
Next
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.